|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
CA2132012C
(en)
|
1992-03-25 |
2003-04-22 |
John W. Shell |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
ATE302597T1
(de)
|
1997-06-06 |
2005-09-15 |
Depomed Inc |
Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
NZ518739A
(en)
|
1999-11-02 |
2004-12-24 |
Depomed Inc |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
MXPA02007254A
(es)
|
2000-02-04 |
2002-12-09 |
Depomed Inc |
Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
WO2002096404A1
(en)
|
2001-05-29 |
2002-12-05 |
Depomed Development Ltd |
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
ES2232302B1
(es)
|
2003-11-07 |
2006-08-01 |
Universitat De Les Illes Balears |
Myo-inositol hexafosfato para uso topico.
|
|
US7741506B2
(en)
|
2005-04-26 |
2010-06-22 |
Berry & Associates, Inc. |
Probe for measuring phytase activity
|
|
US20060241308A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Berry & Associates, Inc. |
Probe for measuring phytase activity
|
|
ES2288126B2
(es)
|
2006-06-01 |
2009-07-06 |
Universitat De Les Illes Balears |
Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
|
|
ES2332636B1
(es)
|
2008-08-06 |
2011-02-10 |
Universitat De Les Illes Balears |
Composicion de liquido de dialisis.
|
|
US8987514B2
(en)
*
|
2009-02-04 |
2015-03-24 |
President And Fellows Of Harvard College |
Compositions and methods for labeling and imaging phospholipids
|
|
GB0920985D0
(en)
|
2009-11-30 |
2010-01-13 |
Queen Mary & Westfield College |
Novel inositol phosphate derivatives
|
|
EP2579036A1
(en)
|
2011-10-06 |
2013-04-10 |
Laboratorios Sanifit, S.L. |
Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
|
|
SMT202100406T1
(it)
|
2015-12-11 |
2021-09-14 |
Eth Zuerich |
Derivati di inositolo per l'uso nella cristallizzazione patologica
|
|
EP3852767B1
(en)
|
2018-09-18 |
2025-12-17 |
Vifor (International) AG |
Calcium oxalate crystallization inhibitors for renal disorders
|
|
WO2021219135A1
(zh)
|
2020-04-30 |
2021-11-04 |
上海森辉医药有限公司 |
一种肌醇衍生物及其用途
|
|
EP4036097A1
(en)
*
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|